<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040660</url>
  </required_header>
  <id_info>
    <org_study_id>MW2018-06-21</org_study_id>
    <nct_id>NCT04040660</nct_id>
  </id_info>
  <brief_title>Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries</brief_title>
  <acronym>NEXT</acronym>
  <official_title>Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediWound Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediWound Ltd</source>
  <brief_summary>
    <textblock>
      Enzymatic eschar removal with NexoBrid allows initiating and completing the phase of removal
      of the offending eschar earlier upon admission, enabling earlier visualization of the wound
      bed for assessment of burn wound depth as well as preservation of viable dermal tissues, as
      further elaborated and supported by previous clinical studies. The depth determination is
      important for the planning and execution of the post eschar removal stage of wound closure
      phase (grafting or spontaneous epithelialization).

      Additional clinically meaningful attributes of NexoBrid enzymatic eschar removal is the
      ability to lower surgical burden as it allows to remove eschar in wounds that otherwise would
      have to undergo surgical excision as no other non-surgical treatment is available for early
      and effective eschar removal.

      MediWound has completed the recruitment of patients to study MW2010-03-02 (DETECT Study). The
      timeline for patients' follow-up and potential for approval in 2021/2022, creates a
      significant gap in the ability of clinical practitioner's to maintain their knowledge and
      skills in using NexoBrid as they no longer treat eligible patients. The expanded access
      protocol will allow to expand treatment to additional patients in up to 30 US burn centers
      (DETECT sites and additional sites), until the completion of the BLA assessment and possible
      marketing authorization of NexoBrid in the US. The proposed protocol will allow product
      availability to eligible population and keep the clinical use of the product knowledge active
      in the burn care community introducing it to their routine burn care.

      The purpose of this treatment protocol is to provide NexoBrid to patients with DPT and FT
      thermal burns on up to 30% TBSA.

      This protocol is also designed to collect and evaluate the safety and clinical performance of
      NexoBrid in this patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an Expanded Access (treatment) protocol to allow ongoing treatment of burn patients
      with NexoBrid following completion of the enrollment stage of protocol MW2010-03-02 (DETECT
      study).

      This protocol is also designed to collect and evaluate the safety and clinical performance of
      NexoBrid in patients suffering from DPT and FT thermal burns.

      Following the enrollment of a patient to the protocol, physicians will identify one or more
      target wounds (TWs) per patient according to the TW definition. All patient's DPT and FT
      burns that comply with the specified entrance criteria will be treated with NexoBrid and,
      therefore, must be designated as TWs. This will further allow an evaluation of the patient's
      systemic safety by allowing treatment of the patient's entire deep burns.

      Prior to initiation of eschar removal treatment, patients will be medicated with appropriate
      analgesia and undergo wound cleansing and dressing of all wounds with antibacterial solutions
      according to product instruction for use in order to ensure clean and moist eschar covered
      wound bed for NexoBrid application. Vital signs (Blood Pressure, Heart Rate and temperature)
      measurements and pain assessment will be performed within 24 hrs before start of treatment as
      well as haematology, biochemistry blood tests &amp; PTT/INR. Pressure measurements for
      circumferential extremity wounds will be performed 1 hour before start of treatment and will
      be closely monitored during treatment. Following wound cleansing and soaking treatments,
      patients will undergo the eschar removal process. TWs of up to 15% total body surface area
      (TBSA) will be treated with a single application of NexoBrid for 4 hours. Patients with TWs
      &gt;15% TBSA and up to 30% TBSA will be treated with 2 consecutive applications of 4 hours each.
      NexoBrid should not be applied to more than 15% TBSA in one session. PK samples will be taken
      from sub-set of patients with TWs area &gt;15% TBSA. Pressure measurements for circumferential
      extremity wounds will be performed after the removal of NexoBrid.

      Post eschar removal completion, patients will undergo daily vital signs (Blood Pressure,
      Heart Rate and temperature measurements) and pain assessments for 1 week, starting on the
      morning following start of eschar removal. Blood tests (haematology and biochemistry) will be
      performed 24 ± 6 hrs post eschar removal as well as PTT/INR. Weekly assessments of wound
      healing progress including the dressings used until complete wound closure will be performed.

      Cosmesis (scar quality) evaluation (using MVSS) will be performed at 3 and 12 months post
      wound closure confirmation visit.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Thermal Burn</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NexoBrid</intervention_name>
    <description>NexoBrid is presented as lyophilized powder and gel vehicle for preparation of a gel for cutaneous use. The API is a concentrate of proteolytic enzymes enriched in Bromelain extracted from the stem of Ananas comosus (pineapple plant)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria patient level:

          1. Males and females ≥ 18 years of age,

          2. Thermal burns caused by fire/flame, scalds or contact,

          3. Patient total burns area ≥ 1% DPT and / or FT with eschar that should be removed in
             SOC,

          4. Patient total burns area to be treated should be ≤ 30% TBSA; SPT, DPT and/or FT in
             depth,

          5. Informed consent can be obtained within 84h of the burn injury,

          6. Patients who are willing and able to sign a written consent . Inclusion Criteria -
             Wound level

               -  At least one wound (a continuous burn area) that is ≥0.5% TBSA (DPT and/or FT)
                  (this minimal wound size should not include face, perineal or genital)

        All planned TWs should meet the following criteria:

          -  SPT areas that cannot be demarcated from DPT and FT areas should be less than 50% of
             the % TBSA of the TW, with eschar that should be removed in SOC,

          -  Wound's blisters can be removed/ unroofed, as judged by the investigator.

        Exclusion Criteria patient level:

          1. Modified Baux index ≥ 80,

          2. Patients with burned, charred fingers, 3rd degree in depth and possibly devoid of
             circulation,

          3. Patients with abraded wound/s that cannot be treated by an enzymatic debrider
             application (NexoBrid),

          4. Patients with pre enrolment escharotomy,

          5. Patients with electrical or chemical burns,

          6. The following pre-enrollment dressings: a. Flammacerium, b. Silver Nitrate (AgNO3),

          7. Patients with pre-enrolment wounds which are covered by eschar heavily saturated with
             Silver, Iodine or by SSD pseudoeschar (pseudoeschar as a result of &gt; 12 hrs SSD
             treatment),

          8. Patients with diagnosed infections as described in the protocol,

          9. Diagnosis of smoke inhalation injury [12],

         10. Pregnant women (serum positive pregnancy test) or nursing mothers,

         11. Poorly controlled diabetes mellitus (HbA1c&gt;11%) in patients with known diabetes as
             captured in the medical history,

         12. BMI greater than 39.0 kg/m2 in patients with burns area of up to 15% TBSA or BMI
             greater than 34.0 kg/m2 in patients with burns area of more than 15% %TBSA,

         13. American Society of Anesthesiologists (ASA) physical status classification system
             greater than 2

         14. Cardio-pulmonary disease (MI within 6 months prior to injury, severe or unstable
             Ischemic Heart Disease, severe or unstable heart failure, severe pulmonary
             hypertension, severe COPD or pre-existing oxygen-dependent pulmonary diseases, severe
             broncho-pneumonia within 1 month prior to injury, steroid dependent asthma or
             uncontrolled asthma),

         15. Pre-existing diseases which interfere with circulation (severe peripheral vascular
             disease, severe circulatory edema and/or lymphedema, regional lymph nodes dissection,
             significant varicose veins),

         16. Any conditions that would preclude safe treatment or adding further risk to the basic
             acute burn trauma (such as severe immuno-compromising diseases, life threatening
             trauma, severe pre-existing coagulation disorder, severe cardiovascular disorder,
             significant pulmonary disorder, significant liver disorder including post alcoholic
             abuse impaired function or neoplastic disease, blast injury),

         17. Chronic systemic steroid intake,

         18. History of allergy and/or known sensitivity to pineapples, papaya, Bromelain or
             papain.

         19. Enrollment in any investigational drug trial within 4 weeks prior to screening.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Limor Klein, PhD</last_name>
    <phone>972-77-9714176</phone>
    <email>limord@mediwound.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keren David-Zarbiv</last_name>
    <phone>972-77-9714103</phone>
    <email>kerend@mediwound.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Andrew Bright, DO</last_name>
      <phone>251-471-7971</phone>
      <email>abright@health.southalabama.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kelley Prutzman, RN</last_name>
    </contact_backup>
    <investigator>
      <last_name>Andrew Bright, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maricopa Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Kevin Foster, MD</last_name>
      <phone>602-344-5624</phone>
      <email>kevin_foster@dmgaz.org</email>
    </contact>
    <contact_backup>
      <last_name>Suzanne Osborne, RN</last_name>
      <phone>602-344-5141</phone>
      <email>suzanne.osborn@mihs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Foster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medstar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jeffrey Shupp, MD</last_name>
      <phone>202-877-7347</phone>
      <email>jeffrey.w.shupp@medstar.net</email>
    </contact>
    <contact_backup>
      <last_name>Melissa McLawhorn</last_name>
      <phone>202-877-6181</phone>
      <email>Melissa.M.Mclawhorn@medstar.net</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Shupp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Joshua Carson, MD</last_name>
      <email>Joshua.Carson@surgery.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tera Thigpin</last_name>
      <phone>352-265-0111</phone>
      <email>tera.thigpin@surgery.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joshua Carson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Louis Pizano, MD</last_name>
      <phone>305-585-1178</phone>
      <email>lpizano@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ron Manning</last_name>
      <phone>305-355-4990</phone>
      <email>rmanning@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Louis Pizano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>lucy wibbenmeyer, MD</last_name>
      <phone>319-356-3551</phone>
      <email>lucy-wibbenmeyer@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Morgan</last_name>
      <phone>319-356-1304</phone>
      <email>elizabeth-morgan@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>lucy wibbenmeyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Lucy Wibbenmeyer, MD</last_name>
      <phone>319-356-1304</phone>
      <email>lucy-wibbenmeyer@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Burnett Burn Center at The University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Dhaval Bhavsar, MD</last_name>
      <phone>913-588-2000</phone>
      <email>dbhavsar@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Reynolds, RN</last_name>
      <phone>913-588-0068</phone>
      <email>jreynolds11@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dhaval Bhavsar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Burn Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Julie Caffrey, MD</last_name>
      <email>jcaffre5@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vidhi Javia</last_name>
      <phone>443-287-7848</phone>
      <email>vjavia1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Caffrey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The General Hospital Corporation d/b/a Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jeremy Goverman, MD</last_name>
      <phone>617-726-3712</phone>
      <email>JGOVERMAN@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Levin, RN</last_name>
      <email>Jlevin7@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jeremy Goverman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hennepin Healthcare</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Frederick Endorf, MD</last_name>
      <email>Frederick.Endorf@hcmed.org</email>
    </contact>
    <contact_backup>
      <last_name>Emily Kittelson</last_name>
      <phone>612-873-6396</phone>
      <email>Emily.Kittelson@hcmed.org</email>
    </contact_backup>
    <investigator>
      <last_name>Frederick Endorf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health Care</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jeffrey Litt, DO</last_name>
      <phone>573-884-6779</phone>
      <email>littjs@health.missouri.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Randolph, RN</last_name>
      <phone>573-882-4387</phone>
      <email>randolphjl@health.missouri.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Litt, MO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New-York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>James Gallagher, MD</last_name>
      <phone>212-746-7913</phone>
      <email>jag9027@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angela Rabbitts, RN</last_name>
      <phone>212-746-5881</phone>
      <email>anr2002@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Gallagher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Medicine Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Adam Singer, Dr</last_name>
      <phone>631-444-7857</phone>
      <email>adam.singer@stonybrookmedicine.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maria (Merry) Taylor, RN</last_name>
      <phone>631-444-8345</phone>
      <email>PhaMaria.Taylor@stonybrookmedicine.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oregon Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>972227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Kristin Hickey</last_name>
      <phone>503-413-5447</phone>
    </contact>
    <investigator>
      <last_name>Michael J Mosier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital and Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Sigrid Blome-Eberwein, MD</last_name>
      <phone>610-402-1485</phone>
      <email>Sigri.Blome-Eberwein@lvhn.org</email>
    </contact>
    <contact_backup>
      <last_name>Mary Sobotor, CCRC</last_name>
      <phone>610-402-1592</phone>
      <email>Mary.Sobotor@lvhn.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sigrid Blome-Eberwein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Firefighters Regional Burn Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>William Hickerson, MD</last_name>
      <phone>901-448-2579</phone>
      <email>whicker@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>William Hickerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Giavonni Lewis, MD</last_name>
      <phone>801-581-8990</phone>
      <email>giavonni.lewis@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Martin Carricaburu</last_name>
      <phone>801-581-3363</phone>
      <email>martin.carricaburu@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Giavonni Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Tam Pham, MD</last_name>
      <phone>206-744-3140</phone>
      <email>tpham94@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily Eschelbach, RN</last_name>
      <phone>206-744-3587</phone>
      <email>eschee13@uw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tam Pham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colombia St Mary's, Inc.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Nicholas Meyer, MD</last_name>
      <email>whicker@uthsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Margaret Wilson</last_name>
      <phone>414-585-1498</phone>
      <email>Margaret.Wilson2@ascension.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nicholas Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

